TY - CONF
T1 - Prevalence of attention deficit hyperactivity disorder symptoms among adult outpatients with substance use disorders in addiction medicine clinic in "Riga Psychiatry and Addiction Medicine Centre"
AU - Ennītis, Mārtiņš
AU - Laizāne, Marta
AU - Landsmane, Inga
AU - Bezborodovs, Ņikita
PY - 2021/3/24
Y1 - 2021/3/24
N2 - Many studies show a link between attention deficit hyperactivity disorder (ADHD) and substance use disorders (SUD). Identifying patients ADHD symptoms could help improve treatment results and quality of life, therefore the aim of this study is to evaluate the prevalence of ADHD symptoms in Riga Psychiatry and Addiction medicine centre (RPNC) outpatient population and study the link between SUD and ADHD. In a period of 30 days all consentient clients of RPNC outpatient addiction clinic who would fit the inclusion criteria were asked to take part in the study. Patients were surveyed for basic sociodemographic data and screened with Adult ADHD Self-report Scale (ASRSv1.1) in Latvian or Russian depending on preferred language. Results were compared between previously diagnosed treatment seeking SUD patients and clients who seek to get a medical allowance of any sort (control group). Out of 312 participants 237 were treatment seeking SUD patients, 75 controls. Mean age was 38.07. 78.2% of the respondents were male, males were also more often being treated for SUD’s 82,7% vs 17,3%.
General prevalence of ADHD symptoms was 19.6% (61 respondents), patients with SUD were significantly more likely to screen positive for ADHD symptoms than control group (23,2% and 8% respectively, p=0.004 using Chi-square equation). In SUD patients group female participants tended to screen positive more often (34,1% vs 20,9%) but the link didn’t reach statistical significance (p=0.068). Among SUD patients education, employment status and nationality were not significant factors for positive ASRS screener. Patients with SUD are more likely to screen positive on ASRS v1.1 than general population. It is important to identify ADHD symptoms in SUD patients, and take them into account when planning the treatment and rehabilitation program.
AB - Many studies show a link between attention deficit hyperactivity disorder (ADHD) and substance use disorders (SUD). Identifying patients ADHD symptoms could help improve treatment results and quality of life, therefore the aim of this study is to evaluate the prevalence of ADHD symptoms in Riga Psychiatry and Addiction medicine centre (RPNC) outpatient population and study the link between SUD and ADHD. In a period of 30 days all consentient clients of RPNC outpatient addiction clinic who would fit the inclusion criteria were asked to take part in the study. Patients were surveyed for basic sociodemographic data and screened with Adult ADHD Self-report Scale (ASRSv1.1) in Latvian or Russian depending on preferred language. Results were compared between previously diagnosed treatment seeking SUD patients and clients who seek to get a medical allowance of any sort (control group). Out of 312 participants 237 were treatment seeking SUD patients, 75 controls. Mean age was 38.07. 78.2% of the respondents were male, males were also more often being treated for SUD’s 82,7% vs 17,3%.
General prevalence of ADHD symptoms was 19.6% (61 respondents), patients with SUD were significantly more likely to screen positive for ADHD symptoms than control group (23,2% and 8% respectively, p=0.004 using Chi-square equation). In SUD patients group female participants tended to screen positive more often (34,1% vs 20,9%) but the link didn’t reach statistical significance (p=0.068). Among SUD patients education, employment status and nationality were not significant factors for positive ASRS screener. Patients with SUD are more likely to screen positive on ASRS v1.1 than general population. It is important to identify ADHD symptoms in SUD patients, and take them into account when planning the treatment and rehabilitation program.
M3 - Abstract
SP - 192
T2 - RSU Research week 2021: Knowledge for Use in Practice
Y2 - 24 March 2021 through 26 March 2021
ER -